PMID- 25806283
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150325
LR  - 20200930
IS  - 2218-6751 (Print)
IS  - 2226-4477 (Electronic)
IS  - 2218-6751 (Linking)
VI  - 3
IP  - 2
DP  - 2014 Apr
TI  - Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.
PG  - 70-4
LID - 10.3978/j.issn.2218-6751.2014.02.02 [doi]
AB  - The echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase 
      (EML4-ALK) has emerged as the second most important driver oncogene in lung 
      cancer and the first targetable fusion oncokinase to be identified in 4-6% of 
      lung adenocarcinomas. Crizotinib, along with a diagnostic test-the Vysis ALK 
      Break Apart fluorescence in situ hybridization (FISH) Probe Kit-is approved for 
      the treatment of ALK positive advanced non-small cell lung cancer (NSCLC). 
      However, the success of a targeted drug is critically dependent on a sensitive 
      and specific screening assay to detect the molecular drug target. In our 
      experience, reverse transcription polymerase chain reaction (RT-PCR)-based 
      detection of EML4-ALK is a more sensitive and reliable approach compared to FISH 
      and immunohistochemistry (IHC). Although ALK FISH is clinically validated, the 
      assay can be technically challenging and other diagnostic modalities, including 
      IHC and RT-PCR should be further explored.
FAU - Teixido, Cristina
AU  - Teixido C
AD  - 1 Pangaea Biotech, Quiron Dexeus University Institute, 08028 Barcelona, Spain, 2 
      Dr Rosell Oncology Institute, Quiron Dexeus University Institute, 08028 
      Barcelona, Spain ; 3 Catalan Institute of Oncology, Hospital Germans Trias i 
      Pujol, 08916 Badalona, Spain.
FAU - Karachaliou, Niki
AU  - Karachaliou N
AD  - 1 Pangaea Biotech, Quiron Dexeus University Institute, 08028 Barcelona, Spain, 2 
      Dr Rosell Oncology Institute, Quiron Dexeus University Institute, 08028 
      Barcelona, Spain ; 3 Catalan Institute of Oncology, Hospital Germans Trias i 
      Pujol, 08916 Badalona, Spain.
FAU - Peg, Vicente
AU  - Peg V
AD  - 1 Pangaea Biotech, Quiron Dexeus University Institute, 08028 Barcelona, Spain, 2 
      Dr Rosell Oncology Institute, Quiron Dexeus University Institute, 08028 
      Barcelona, Spain ; 3 Catalan Institute of Oncology, Hospital Germans Trias i 
      Pujol, 08916 Badalona, Spain.
FAU - Gimenez-Capitan, Ana
AU  - Gimenez-Capitan A
AD  - 1 Pangaea Biotech, Quiron Dexeus University Institute, 08028 Barcelona, Spain, 2 
      Dr Rosell Oncology Institute, Quiron Dexeus University Institute, 08028 
      Barcelona, Spain ; 3 Catalan Institute of Oncology, Hospital Germans Trias i 
      Pujol, 08916 Badalona, Spain.
FAU - Rosell, Rafael
AU  - Rosell R
AD  - 1 Pangaea Biotech, Quiron Dexeus University Institute, 08028 Barcelona, Spain, 2 
      Dr Rosell Oncology Institute, Quiron Dexeus University Institute, 08028 
      Barcelona, Spain ; 3 Catalan Institute of Oncology, Hospital Germans Trias i 
      Pujol, 08916 Badalona, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Transl Lung Cancer Res
JT  - Translational lung cancer research
JID - 101646875
PMC - PMC4367661
OTO - NOTNLM
OT  - Anaplastic lymphoma kinase (ALK)
OT  - fluorescence in situ hybridization (FISH)
OT  - immunohistochemistry (IHC)
OT  - non-small cell lung cancer (NSCLC)
OT  - reverse transcription-polymerase chain reaction (RT-PCR)
EDAT- 2015/03/26 06:00
MHDA- 2015/03/26 06:01
PMCR- 2014/04/01
CRDT- 2015/03/26 06:00
PHST- 2014/02/20 00:00 [received]
PHST- 2014/02/25 00:00 [accepted]
PHST- 2015/03/26 06:00 [entrez]
PHST- 2015/03/26 06:00 [pubmed]
PHST- 2015/03/26 06:01 [medline]
PHST- 2014/04/01 00:00 [pmc-release]
AID - tlcr-03-02-070 [pii]
AID - 10.3978/j.issn.2218-6751.2014.02.02 [doi]
PST - ppublish
SO  - Transl Lung Cancer Res. 2014 Apr;3(2):70-4. doi: 
      10.3978/j.issn.2218-6751.2014.02.02.